Get the Stockscreener App
7.07
0.14%
-0.010
Sagimet Biosciences Inc stock is traded at $7.07, with a volume of 250.71K.
It is down -0.14% in the last 24 hours and down -30.96% over the past month.
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.
See More
Previous Close:
$7.08
Open:
$7.12
24h Volume:
250.71K
Relative Volume:
0.16
Market Cap:
$219.18M
Revenue:
-
Net Income/Loss:
$-29.25M
P/E Ratio:
-5.9612
EPS:
-1.186
Net Cash Flow:
$-22.80M
1W Performance:
+2.32%
1M Performance:
-30.96%
6M Performance:
+84.11%
1Y Performance:
+127.33%
1-Day Range:
$6.97
$7.2533
1-Week Range:
$6.5323
$7.48
52-Week Range:
$1.73
$11.41
Sagimet Biosciences Inc Stock (SGMT) Company Profile
Name
Sagimet Biosciences Inc
Sector
Industry
Phone
(650) 561-8600
Address
155 BOVET RD., SUITE 303, SAN MATEO
Compare SGMT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SGMT
Sagimet Biosciences Inc
|
7.07 | 245.54M | 0 | -29.25M | -22.80M | -1.186 |
|
VRTX
Vertex Pharmaceuticals Inc
|
387.18 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
587.65 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
451.20 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
708.09 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
308.91 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Sagimet Biosciences Inc Stock (SGMT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-11-25 | Initiated | Wedbush | Outperform |
| Aug-07-25 | Resumed | H.C. Wainwright | Buy |
| Jul-24-25 | Initiated | Canaccord Genuity | Buy |
| Dec-06-24 | Initiated | Oppenheimer | Outperform |
| Nov-12-24 | Initiated | UBS | Buy |
| Jun-28-24 | Downgrade | Goldman | Buy → Neutral |
| May-02-24 | Initiated | H.C. Wainwright | Buy |
| Mar-25-24 | Initiated | Leerink Partners | Outperform |
| Aug-08-23 | Initiated | Goldman | Buy |
| Aug-08-23 | Initiated | JMP Securities | Mkt Outperform |
| Aug-08-23 | Initiated | Piper Sandler | Overweight |
| Aug-08-23 | Initiated | TD Cowen | Outperform |
View All
Sagimet Biosciences Inc Stock (SGMT) Latest News
Using data filters to optimize entry into Sagimet Biosciences Inc.Oil Prices & High Return Trade Opportunity Guides - Newser
Sagimet Biosciences Inc. stock chart pattern explainedJuly 2025 News Drivers & Accurate Entry and Exit Point Alerts - Newser
Sagimet Biosciences Inc. recovery potential after sell offMarket Trend Summary & Daily Technical Forecast Reports - Newser
Sagimet Biosciences shares rise 1.13% intraday after announcing participation in two upcoming investor conferences. - AInvest
Backtesting results for Sagimet Biosciences Inc. trading strategiesInflation Watch & Free Expert Verified Stock Movement Alerts - Newser
Clinical-Stage Biotech Sagimet Biosciences Set for Key Investor Presentations at Major September Conferences - Stock Titan
Will Sagimet Biosciences Inc. price bounce be sustainablePortfolio Update Summary & Daily Stock Trend Watchlist - Newser
Sagimet Biosciences Inc.’s volatility index tracking explainedEarnings Overview Report & Stock Market Timing Techniques - Newser
How to build a dashboard for Sagimet Biosciences Inc. stockTrade Analysis Summary & Safe Swing Trade Setups - Newser
Earnings visualization tools for Sagimet Biosciences Inc.Weekly Profit Report & Low Drawdown Investment Ideas - Newser
Sector ETF performance correlation with Sagimet Biosciences Inc.Market Trend Review & Growth Focused Stock Reports - Newser
What to do if you’re stuck in Sagimet Biosciences Inc.2025 Market Overview & Low Drawdown Momentum Ideas - Newser
How high can Sagimet Biosciences Inc. stock price go in 2025Weekly Trend Recap & Community Trade Idea Sharing - Newser
Will Sagimet Biosciences Inc. outperform the marketJuly 2025 Opening Moves & Verified Chart Pattern Signals - Newser
What indicators show strength in Sagimet Biosciences Inc.Trade Volume Summary & AI Powered Buy and Sell Recommendations - Newser
Top chart patterns to watch in Sagimet Biosciences Inc.Market Sentiment Review & Safe Swing Trade Setup Alerts - Newser
Is Sagimet Biosciences Inc. still worth holding after the dipTrade Exit Summary & Technical Pattern Based Buy Signals - Newser
How sentiment analysis helps forecast Sagimet Biosciences Inc.Trade Analysis Summary & Free Technical Pattern Based Buy Signals - Newser
How Sagimet Biosciences Inc. stock performs during market volatilityRecession Risk & Verified Momentum Watchlists - Newser
Investor Mood: Is Sagimet Biosciences Inc. stock a good pick for beginnersTrend Reversal & Weekly High Return Stock Forecasts - theviewers.co.kr
Sagimet Biosciences appoints KPMG as new auditor, replaces Deloitte By Investing.com - Investing.com Nigeria
Sagimet Biosciences appoints KPMG as new auditor, replaces Deloitte - Investing.com
Sagimet Biosciences Inc. Volume Confirms Breakout — Analysts BullishWeekly Gains Summary & Low Volatility Stock Suggestions - beatles.ru
Will Sagimet Biosciences Inc. Benefit From Sector TailwindsTrade Analysis Report & High Conviction Investment Ideas - 더경남뉴스
Real time scanner hits for Sagimet Biosciences Inc. explainedWeekly Trend Recap & Technical Confirmation Alerts - Newser
Sagimet Biosciences Inc. (SGMT) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
After Plunging 28% in 4 Weeks, Here's Why the Trend Might Reverse for Sagimet Biosciences Inc. (SGMT) - Yahoo Finance
Is Sagimet Biosciences Inc. building a consolidation base2025 Support & Resistance & Daily Profit Focused Stock Screening - Newser
Analysts' Top Picks in Healthcare Sector: Outlook Therapeutics, Pfizer, Sagimet Biosciences, Inc. - AInvest
Can Sagimet Biosciences Inc. recover in the next quarterInsider Buying & Fast Gain Stock Trading Tips - Newser
Risk adjusted return profile for Sagimet Biosciences Inc. analyzedPortfolio Risk Report & Real-Time Market Trend Scan - Newser
Promising Clinical Developments and Strategic Positioning Make Sagimet Biosciences a Buy - TipRanks
Analysts’ Top Healthcare Picks: Outlook Therapeutics (OTLK), Pfizer (PFE) - The Globe and Mail
Promising Growth Potential of Sagimet Biosciences: Buy Rating Justified by Strategic Trials and Strong Financial Position - TipRanks
Wall Street Analysts Predict a 437.05% Upside in Sagimet Biosciences Inc. (SGMT): Here's What You Should Know - MSN
Custom watchlist performance reports with Sagimet Biosciences Inc.2025 Market Overview & Daily Price Action Insights - Newser
Will earnings trigger a reversal in Sagimet Biosciences Inc.Earnings Overview Report & Real-Time Buy Zone Alerts - Newser
Why Sagimet Biosciences Inc. stock attracts strong analyst attentionGap Up & Growth Focused Stock Reports - Newser
What data driven models say about Sagimet Biosciences Inc.’s futureShare Buyback & High Accuracy Swing Trade Signals - Newser
Is Sagimet Biosciences Inc. stock bottoming outInsider Buying & Free Verified High Yield Trade Plans - Newser
Screener Results Flag Sagimet Biosciences Inc. as OversoldEarnings Growth Summary & Risk Controlled Stock Alerts - beatles.ru
Sagimet Biosciences Inc. Stock Performance After Earnings: Historical InsightsQuarterly Growth Report & Daily Momentum Trading Reports - Newser
News impact scoring models applied to Sagimet Biosciences IncEarnings Overview Report & Low Drawdown Trading Techniques - Newser
News impact scoring models applied to Sagimet Biosciences Inc.July 2025 Outlook & Precise Trade Entry Recommendations - Newser
A Quick Look at Today's Ratings for Sagimet Biosciences(SGMT.US), With a Forecast Between $25 to $29 - 富途牛牛
Sagimet Biosciences: Promising Advancements in FASN Inhibitor Platform and Strategic Growth Initiatives Justify Buy Rating - TipRanks
Promising Potential of Sagimet Biosciences’ FASN Inhibitors Drives Buy Rating - TipRanks
Sagimet Biosciences Advances FASN Inhibitor Trials for Acne and MASH, Reports Q2 Earnings - AInvest
Brokers Set Expectations for SGMT Q2 Earnings - Defense World
Sagimet Biosciences Reports Progress in Acne and MASH Trials - TipRanks
Sagimet Biosciences Enters New Sales Agreement with Leerink - TipRanks
Sagimet Biosciences Inc Stock (SGMT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Sagimet Biosciences Inc Stock (SGMT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Martins Eduardo Bruno | Chief Medical Officer |
Jul 21 '25 |
Sale |
9.13 |
8,277 |
75,607 |
106,936 |
| Rozek Elizabeth | General Counsel and CCO |
Jul 21 '25 |
Sale |
9.13 |
10,780 |
98,471 |
183,726 |
0.95%
0.90%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):